Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993455 | 1.00 | KDM1A (0.52) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL6959970 | 1.00 | KDM1A (0.52) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL6970469 | 1.00 | KDM1A (0.52) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL6968834 | 1.00 | KDM1A (0.52) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL7885006 | 0.88 | KDM1A (0.59) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL7886359 | 0.88 | KDM1A (0.59) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL7882072 | 0.88 | KDM1A (0.59) | KDM1AGPR119TSHRALOX15MAPK1 | |
| SCHEMBL31415666 | 0.84 | MEN1 (0.46) | KDM1A | |
| SCHEMBL31758554 | 0.84 | GPR119 (0.41) | KDM1AGPR119TSHRALOX15HDAC1 | |
| SCHEMBL14272817 | 0.83 | KDM1A (0.48) | KDM1AGPR119TSHRALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | KDM1A 1062/4885GPR119 354/4885TSHR 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.